Brian Bonilla on Muck Rack

Brian Bonilla

Verified
New York
As seen in: Ad Age, Nature, Time Out New York, ACS Publications, Cell Reports, Crain's New York Business, Odyssey, Automotive News, Crain's Chicago Business, Crain's Detroit Business, Brooklyn Magazine and
Senior reporter at @AdAge. Also words in Timeout and Brooklyn Magazine

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

OpenAI reveals more of its ChatGPT ads playbook

|
By Brian Bonilla Verified, Ewan Larkin Verified, Gillian Follett Verified
| Gear Open
What Microsoft’s product-focused ad strategy means for Copilot and how it’s connecting with creators
Open in Who Shared Issue with article?

City is looking for an agency to brand its city-run grocery stores

|
By Brian Bonilla Verified
| Crain's New York Business Verified
May 29, 2026 11:56 AM EDT The New York City Economic Development Corporation has launched an agency RFP for one of Mayor Zohran Mamdani’s first major projects in office. It’s looking for a branding or design agency to shape the identity of “N.Y.C. Groceries,” an initiative intended to launch five city-supported grocery stores across the city, one in each borough.
Open in Who Shared Issue with article?

Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21

|
By Prabhanshu Tripathi, Ja-Hyun Koo, Xuejun Chen, Marlon Dillon, Baoshan Zhang, Mariah Lofgren, Katelyn Nguyen, I-Ting Teng, Brian Bonilla Verified, Wing-Pui Kong, Amy Henry, Tyler Stephens, Yaroslav Tsybovsky, Stephanie R. Weldon, Daniel Douek, Theodore C. Pierson, Facundo D. Batista, Azza H Idris, Robert A. Seder, Peter D. Kwong, Tongqing Zhou, Sarah Kerscher
| Nature Verified
Abstract Repetitive display of the major repeats of the Plasmodium falciparum circumsporozoite protein (PfCSP) is the basis for two WHO-recommended vaccines: RTS,S/AS01 and R21/Matrix-M. Recently, however, the CIS43 monoclonal antibody that preferentially targets the junctional region of PfCSP has been shown to be highly protective in humans, highlighting its junctional epitope as a key vaccine target.
Open in Who Shared Issue with article?
See all 51 licensed articles (1,654 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified